|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C12Q 1/68 |
| (11) | Patento numeris | 2820151 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13707527.1 |
| Europos patento paraiškos padavimo data | 2013-02-22 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-01-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-03-25 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2013/027441 |
| Data | 2013-02-22 |
| (87) | Numeris | WO 2013/130364 |
| Data | 2013-09-06 |
| (30) | Numeris | Data | Šalis |
| 201261604290 P | 2012-02-28 | US |
| (72) |
CONG, Feng, US
HAO, Huaixiang, US
HSIEH, Hsin-i, US
JIANG, Xiaomo, US
LIU, Jun, US
NG, Nicholas, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |
| CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |